Corcept's 31.7% YoY revenue surge in 2026Q2 to $256.1M, driven by its lead product Korlym, underscores robust commercial execution and a fortress balance sheet (D/E of 0.01). However, the looming Hatch-Waxman litigation with Teva and potential generic entry po...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 31.7% YoY in 2026Q2, with gross margin holding at 98.4%, though SG&A escalation (up 88% since 2024Q4) compressed operating margin to 16.1%.
The March 2026 approval of ROSELLA transitioned it from a trial story to a launch story, bolstering confidence in its potential as a significant ovarian-cancer franchise.
Corcept retains a profitable base business with 2026 revenue guidance of $900-$1,000 million and holds $532.4 million in cash, cash equivalents, and marketable securities.
Despite risks, the relacorilant NDA represents a key growth driver, with its approval potentially driving significant upside for the company.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $0.36+1383.3% vs $0.02 | $256M+15.8% vs $221M |
Q2 2026 Apr 30, 2026 | -$0.30-172.3% vs -$0.11 | $165M-11.0% vs $185M |
Q1 2026 Feb 24, 2026 | $0.20-39.4% vs $0.33 | $202M-20.7% vs $255M |
Q4 2025 Nov 4, 2025 | $0.16-11.1% vs $0.18 | $208M-18.7% vs $255M |
Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.
Corcept Therapeutics Incorporated (NASDAQ: CORT - Get Free Report) insider Roberto Vieira sold 296 shares of the firm's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $100.82, for a total transaction of $29,842.72. Following the transaction, the insider directly owned 3,946 shares in the company, valued at
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined wit.
Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
Benchmark CORT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Corcept Therapeutics Incorporated (CORT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $112.94 | $12.12B | 137.73 | 12.79% | 13.09% | 15.01% | — | |
| $20.24 | $1.49B | 6.13 | 18.52% | 80.56% | 30.03% | — | |
| $40.48 | $2.34B | 14.94 | 21.51% | 18.88% | 20.06% | — | |
| $43.39 | $2.52B | -63.81 | 8.63% | -13.23% | -10.42% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — | |
| $34.10 | $1.38B | 28.66 | 27.37% | 6.57% | 28.67% | — |
Corcept Therapeutics Incorporated (CORT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Corcept Therapeutics Incorporated (CORT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jun 17, 2026·SEC
Jun 3, 2026·SEC
Get notified when CORT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Corcept Therapeutics Incorporated (CORT) stock FAQ — growth, dividends, profitability & financials explained
Corcept Therapeutics Incorporated (CORT) reported $830.8M in revenue for fiscal year 2025.
Corcept Therapeutics Incorporated (CORT) grew revenue by 12.8% over the past year. This is steady growth.
Yes, Corcept Therapeutics Incorporated (CORT) is profitable, generating $54.9M in net income for fiscal year 2025 (13.1% net margin).
Corcept Therapeutics Incorporated (CORT) has a return on equity (ROE) of 15.0%. This is reasonable for most industries.
Corcept Therapeutics Incorporated (CORT) generated $106.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
